

Leila B Giron

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4262334/publications.pdf>

Version: 2024-02-01

34
papers

746
citations

623734

14
h-index

610901

24
g-index

41
all docs

41
docs citations

41
times ranked

1421
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial. <i>AIDS Research and Therapy</i> , 2022, 19, 2.	1.7	3
2	Examining the Impact of Galectin-9 on. <i>Methods in Molecular Biology</i> , 2022, 2442, 463-474.	0.9	0
3	Viral and Host Biomarkers of HIV Remission Post Treatment Interruption. <i>Current HIV/AIDS Reports</i> , 2022, , 1.	3.1	3
4	Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF- κ B signaling. <i>JCI Insight</i> , 2022, 7, .	5.0	23
5	Abnormal food timing and predisposition to weight gain: Role of barrier dysfunction and microbiota. <i>Translational Research</i> , 2021, 231, 113-123.	5.0	13
6	Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption. <i>MBio</i> , 2021, 12, .	4.1	15
7	COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions. <i>MBio</i> , 2021, 12, .	4.1	53
8	Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV. <i>Nature Communications</i> , 2021, 12, 3922.	12.8	31
9	Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 686240.	4.8	97
10	Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1349-1361.	4.9	3
11	HCV genotype profile in Brazil of mono-infected and HIV co-infected individuals: A survey representative of an entire country. <i>PLoS ONE</i> , 2020, 15, e0227082.	2.5	9
12	Hepatitis C virus modulates IgG glycosylation in HIV co-infected antiretroviral therapy suppressed individuals. <i>Aids</i> , 2020, 34, 1461-1466.	2.2	2
13	Sialyl-LewisX Glycoantigen Is Enriched on Cells with Persistent HIV Transcription during Therapy. <i>Cell Reports</i> , 2020, 32, 107991.	6.4	16
14	The African natural product knipholone anthrone and its analogue anthralin (dithranol) enhance HIV-1 latency reversal. <i>Journal of Biological Chemistry</i> , 2020, 295, 14084-14099.	3.4	6
15	Interferon- λ alters host glycosylation machinery during treated HIV infection. <i>EBioMedicine</i> , 2020, 59, 102945.	6.1	11
16	Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint. <i>Aids</i> , 2020, 34, 681-686.	2.2	26
17	Sialylation and fucosylation modulate inflammasome-activating eIF2 Signaling and microbial translocation during HIV infection. <i>Mucosal Immunology</i> , 2020, 13, 753-766.	6.0	24
18	Nicotinamide activates latent HIV-1 ex vivo in ART suppressed individuals, revealing higher potency than the association of two methyltransferase inhibitors, chaetocin and BIX01294. <i>Brazilian Journal of Infectious Diseases</i> , 2020, 24, 150-159.	0.6	14

#	ARTICLE	IF	CITATIONS
19	Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 592-600.	2.5	29
20	TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes. <i>EBioMedicine</i> , 2019, 45, 328-340.	6.1	22
21	Laboratory surrogate markers of residual HIV replication among distinct groups of individuals under antiretroviral therapy. <i>PLoS ONE</i> , 2019, 14, e0217502.	2.5	2
22	Glycosylation of Zika Virus is Important in Host-Virus Interaction and Pathogenic Potential. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5206.	4.1	37
23	Breaking the Glyco-Code of HIV Persistence and Immunopathogenesis. <i>Current HIV/AIDS Reports</i> , 2019, 16, 151-168.	3.1	26
24	Galectin-9 Mediates HIV Transcription by Inducing TCR-Dependent ERK Signaling. <i>Frontiers in Immunology</i> , 2019, 10, 267.	4.8	34
25	CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	105
26	Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy. <i>Journal of Leukocyte Biology</i> , 2018, 104, 461-471.	3.3	38
27	Thalidomide is Associated With Increased T Cell Activation and Inflammation in Antiretroviral-naïve HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety. <i>EBioMedicine</i> , 2017, 23, 59-67.	6.1	21
28	Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy. <i>Journal of the International AIDS Society</i> , 2017, 20, e25015.	3.0	9
29	High prevalence and incidence of HIV-1 in a counseling and testing center in the city of Itajaí, Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2015, 19, 631-635.	0.6	10
30	Human gammaherpesviruses viraemia in HIV infected patients. <i>Journal of Clinical Pathology</i> , 2015, 68, 726-732.	2.0	3
31	In Vivo HIV-1 Hypermutation and Viral Loads Among Antiretroviral-Naïve Brazilian Patients. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 867-880.	1.1	6
32	Impact of Epstein-Barr virus load, virus genotype, and frequency of the 30%bp deletion in the viral BNLF1 gene in patients harboring the human immunodeficiency virus. <i>Journal of Medical Virology</i> , 2013, 85, 2110-2118.	5.0	5
33	Comparative Effectiveness of Dried-Plasma Hepatitis B Virus Viral Load (VL) Testing in Three Different VL Commercial Platforms Using ViveST for Sample Collection: Fig 1. <i>Journal of Clinical Microbiology</i> , 2012, 50, 145-147.	3.9	2
34	Single-cell glycomics analysis by CyTOF-Lec reveals glycan features defining cells differentially susceptible to HIV. <i>ELife</i> , 0, 11, .	6.0	11